[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lars---low-anterior-resection-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lars---low-anterior-resection-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,51,79,100,128,151,175,202,230],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100588083","phase-3-improving-functional-outcomes-and-quality-of-life-in-patients-with-rectal-cancer-after-surgery-with-intensified-follow-up--surveillance-100588083",false,"NCT06936774","Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance","Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance - a Randomized Controlled Trial (iRECOVER)","iRECOVER","Inclusion Criteria:\n\n* patients older than 18 years\n* patients with rectal cancer in the middle and lower third of the rectum in stages I to IV who underwent LAR with TME and protective ileostomy\n* able to give informed consent as documented by signature\n\nExclusion Criteria:\n\n* dementia or other psychiatric disorder that would prevent the patients from answering the questionnaires and experiencing sustainable training effects\n* impossibility of stoma reversal due to persistent anastomotic leak and\u002For local recurrence","ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical study is to gain further insights into the treatment of patients with Low Anterior Resection Syndrome (LARS) symptoms after rectal resection. The main question is: Can LARS symptoms and quality of life be improved by implementing an intensified follow-up program? Researchers will compare the results of the intervention group with the results of a control group in which patients do not receive an intensified follow-up program to determine whether the intervention works. Participants will undergo an intensified follow-up program which consists of several follow-up visits and medical treatment, pelvic floor muscle training and gynaecological and urological co-treatment in case of LARS symptoms and urinary or sexual complaints.",[27,28,29,30],"LARS - Low Anterior Resection Syndrome","Rectal Cancer Surgery","Rectal Cancer","Quality of Life (QOL)",[32,33,34,35,36,37],"LARS","Low Anterior Resection Syndrome","Intensified follow-up","Rectal cancer","Rectal resection","Low anterior resection","RECRUITING","2026-04-30",{"date":41,"type":42},"2026-05-06","ACTUAL",{"date":44,"type":42},"2025-12-01",{"date":46,"type":21},"2028-07-01",{"name":48,"class":49},"University Hospital, Basel, Switzerland","OTHER",5,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100537158","personalized-care-pathways-for-bowel-symptoms-in-rectal-cancer-patientsdevelopment-of-e-diary-100537158","NCT06274190","Personalized Care Pathways for Bowel Symptoms in Rectal Cancer patients_development of E-diary","Towards Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients Through Precision Medicine","Treatable","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF).\n* Proficient in reading, comprehending, and conversing in Dutch .\n* Patients after rectal surgery for rectal cancer or under Watch and Wait protocol (also referred to as active surveillance).\n\nExclusion Criteria:\n\n* The participant has undergone a different type of surgery, including a Hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgery, or sigmoid resection.\n* Experienced fecal incontinence prior to undergoing surgery.\n* Are affected by neurological disorders affecting bowel function.\n* Already underwent previous pelvic radiation or rectal surgery for non-cancer reasons.",{"count":60,"type":21},158,[62],"NA","Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection, combined with chemoradiotherapy. However, this treatment will negatively impact different aspects of bowel function and the patients' quality of life. These bowel symptoms often remain prevalent, even at 12 months after RC treatment. Most assessment tools are however not capable of capturing the full range or therapeutic-related evolution of these bowel symptoms. Consequently, the aim is to develop a validated bowel diary for diagnosing and evaluation of all bowel symptoms.\n\nIn recent years, organ-preserving strategies such as Watch and Wait have become more widely implemented. Although these patients avoid surgical morbidity, emerging evidence shows that neoadjuvant radiotherapy alone can also cause substantial and persistent bowel dysfunction. Therefore, the study population was expanded to include patients managed with a Watch and Wait strategy in addition to those undergoing TME\u002FPME.",[29,27],[66,67,68],"Bowel diary","Quality of Life (QoL)","Care pathway","2026-04-13",{"date":71,"type":42},"2026-04-15",{"date":73,"type":42},"2024-04-29",{"date":75,"type":21},"2026-07",{"name":77,"class":49},"KU Leuven",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":56,"acronym":57,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":78},"100586351","personalized-care-pathways-for-bowel-symptoms-in-rectal-cancer-patientscontributing-factors-treatable-100586351","NCT06914245","Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients_contributing Factors (Treatable)","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF).\n* Proficient in reading, comprehending, and conversing in Dutch.\n* Patients scheduled for Total Mesorectal Excision (TME) or Partial Mesorectal Excision (PME) or 'Watch and wait' protocol due to rectal cancer.\n\nExclusion Criteria:\n\n* The participant has undergone a different type of surgery, including a Hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgery, or sigmoid resection.\n* Experienced fecal incontinence prior to undergoing surgery.\n* Are affected by neurological disorders affecting bowel function.\n* Already underwent previous pelvic radiation or rectal surgery for non-cancer reasons.\n* Has a permanent stoma.",{"count":86,"type":21},150,[62],"Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection combined with chemoradiotherapy. However, this treatment negatively affects various aspects of bowel function and patients' quality of life. These bowel symptoms often remain prevalent, even 12 months after RC treatment.\n\nThe aim of this study is to identify the factors contributing to persistent bowel symptoms and their long-term impact on quality of life following treatment for rectal cancer, assessed 12 months after surgery or stoma closure in surgically treated patients, and 12 months after completion of neoadjuvant therapy in patients managed with active surveillance\u002Fwatch-and-wait. These insights are crucial for developing an effective care approach, as they help determine when specific evaluations should be conducted and which treatments should be applied at different stages.",[29,27,90],"Active Surveillance",[66,67,68],"2026-01-22",{"date":94,"type":42},"2026-01-23",{"date":96,"type":42},"2025-04-28",{"date":98,"type":21},"2028-12",{"name":77,"class":49},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":78},"100619075","prolars-trial-prospective-longitudinal-follow-up-of-low-anterior-resection-syndrome-lars-and-corefo-score-after-rectum-surgery-in-patients-undergoing-upfront-surgery-or-different-neo-adjuvant-treatment-regimens-100619075","NCT07339904","ProLARS Trial: Prospective Longitudinal Follow-up of Low Anterior Resection Syndrome (LARS) and COREFO Score After Rectum Surgery in Patients Undergoing Upfront Surgery or Different Neo-adjuvant Treatment Regimens","ProLARS","Inclusion Criteria:\n\n* 18 years or older.\n* Diagnosis of rectal cancer, discussed at the multidisciplinary consultation, with the intention to perform a sphincter preserving total mesorectal excision (TME) or partial mesorectal excision (PME), regardless of the need of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* History of inflammatory bowel disease (Crohn's disease, ulcerative colitis) due to often persistent bowel complaints and therefore distorted baseline and follow-up data.\n* Dementia or intellectual disability.\n* Patients who are obstructive and in need a decompressive stoma or rectal stenting due to the lack of baseline data as they are often admitted to the hospital in an urgent setting",{"count":108,"type":21},100,[62],"OBJECTIVE Low anterior resection syndrome (LARS) is a term for functional bowel complaints occurring after low anterior resection. Symptoms can range from faecal incontinence and frequent loose stools to urgency and incomplete emptying with great impact on quality of life. Little is known about the longitudinal evolution of LARS and the impact of different schedules of neoadjuvant chemoradiotherapy combined with surgery.\n\nThe investigators aim to investigate the incidence and evolution of functional bowel complaints in function of different neoadjuvant treatment regimens, type of surgery and adjuvant therapy in patients who undergo surgery for rectal cancer. The investigators focus on following objectives: evolution of LARS- and COREFO-scores per treatment regimen and their impact on work incapacity; identification of possible risk factors potentially related to functional outcome; monitoring and treatment of LARS.\n\nMETHODS This will be a multicentre prospective interventional study. The study population will consist of adult patients with rectal cancer, regardless of any neo-adjuvant therapy. Patients will be included for 5 years with a 2 year postoperative follow-up. Interim analysis will be made after 2 years of inclusion. Patients with intellectual disability or clinical colon obstruction are excluded. Automated online questionnaires including LARS and COREFO scores, incapacity for work and defecation quality will be sent at different time points (figure 1) using REDCap.\n\nRESULTS and CONCLUSIONS Longitudinal change of LARS- and COREFO-scores will be visually summarized. Patient, disease or procedure specific risk factors will be assessed as well.\n\nLARS is proven to be the principal postoperative problem after rectal surgery. If the investigators can predict the severity of LARS (minor or major LARS), this can be extremely helpful in deciding whether to perform a sphincter-sparing resection or a rectal amputation instead. Furthermore, the investigators want to offer perspective to patients who are susceptible to a disturbed postoperative bowel function.",[112,27,113,114,115],"Rectal Adenocarcinoma","Rectal Resection","Low Anterior Resection","Total Mesorectal Excision",[32,36,117,37,118],"Total mesorectal excision","Rectal carcinoma","2026-01-05",{"date":121,"type":42},"2026-01-14",{"date":123,"type":42},"2024-08-26",{"date":125,"type":21},"2029-08",{"name":127,"class":49},"University Hospital, Antwerp",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100599300","the-efficacy-of-antegrade-and-retrograde-enemas-management-in-low-anterior-resection-syndrome-and-improving-the-rate-of-ileostomy-reversal-100599300","NCT07082699","The Efficacy of Antegrade and Retrograde Enemas Management in Low Anterior Resection Syndrome and Improving the Rate of Ileostomy Reversal","The Efficacy of Antegrade and Retrograde Enemas in the Management of Low Anterior Resection Syndrome and Improving the Rate of Ileostomy Reversal: A Single-Centre, Prospective Randomised Controlled Trial","Inclusion Criteria:\n\n1. According to the NCCN guidelines for the pathological diagnosis of rectal cancer, the patient has primary rectal adenocarcinoma;\n2. Age ≥ 18 years;\n3. Previously underwent rectal resection with prophylactic ileostomy via laparoscopy, robotics, or open surgery;\n4. Expected to undergo ileostomy reversal surgery within 1-2 months;\n5. Possesses normal cognitive and communication abilities;\n6. Voluntarily participates in this study and has signed an informed consent form.\n\nExclusion Criteria:\n\n1. American Society of Anesthesiologists (ASA) classification III or higher;\n2. Concurrent inflammatory bowel disease, Crohn's disease, or other intestinal diseases;\n3. Mental disorders, long-term use of psychiatric drugs;\n4. Contraindications to enemas.","80 Years",{"count":137,"type":21},72,[62],"Anterior rectal resection has become the primary surgical treatment for rectal cancer. However, studies have reported that up to 80%-90% of patients who undergo anterior rectal resection experience varying degrees of defecation dysfunction after surgery, such as frequent bowel movements, urgent bowel movements, and faecal incontinence, known as low anterior resection syndrome (LARS). This can lead to a decline in quality of life after surgery and even partial loss of social functioning.",[27],"NOT_YET_RECRUITING","2025-07-22",{"date":144,"type":42},"2025-07-24",{"date":146,"type":21},"2025-07-20",{"date":148,"type":21},"2026-12-30",{"name":150,"class":49},"Sichuan Cancer Hospital and Research Institute",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":78},"100598476","effect-of-thread-embedding-acupuncture-on-postoperative-ileus-recovery-after-colorectal-cancer-surgery-a-multicenter-randomized-controlled-trial-100598476","NCT07071987","Effect of Thread Embedding Acupuncture on Postoperative Ileus Recovery After Colorectal Cancer Surgery: A Multicenter Randomized Controlled Trial","A Multicenter, Randomized Controlled Trial to Evaluate the Efficacy of Thread Embedding Acupuncture in Reducing Postoperative Ileus After Colorectal Cancer Surgery","THREAD-POI","Inclusion Criteria:\n\nAge 18-80 years Diagnosed with stage I-III colorectal cancer Scheduled for elective laparoscopic colorectal resection ASA Physical Status I-III Ability to provide informed consent\n\nExclusion Criteria:\n\nHistory of prior major abdominal surgery Emergency or palliative surgery Combined organ resection or open conversion Severe postoperative complications (e.g., anastomotic leak, GI bleeding) Severe cardiac, hepatic, renal, or psychiatric comorbidities Refusal to undergo acupuncture",{"count":160,"type":21},300,[62],"This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of thread embedding acupuncture (TEA) in promoting gastrointestinal recovery after laparoscopic colorectal cancer surgery. The primary outcome is the time to first flatus. Secondary outcomes include time to first defecation, tolerance to oral intake, length of hospital stay, and patient-reported quality of life.",[164,165,27],"Colorectal Cancer","Postoperative Ileus","2025-07-16",{"date":168,"type":42},"2025-07-18",{"date":170,"type":21},"2025-08-01",{"date":172,"type":21},"2027-07-31",{"name":174,"class":49},"Northern Jiangsu People's Hospital",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":184,"phases":4,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":5},"100587035","a-randomised-clinical-investigation-to-assess-efficacy-of-low-volume-transanal-irrigation-by-qufora-irrisedo-minigo-versus-conservative-treatment-for-low-anterior-resection-syndrome-patients-100587035","NCT06923150","A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients","MINIGO","Inclusion Criteria:\n\n1. Adult aged from 18 years\n2. Patients electively treated for rectal cancer with a low anterior resection\n3. Between 3 and 18 months after the conservative colorectal surgery or 3 and 18 months after the stoma reversal if applicable\n4. LARS score \\>= 25 (minor or major LARS) (Emmertsen and Laurberg 2012) AND LARS definition as consensus with at least one symptom that results in at least one consequence (Keane et al. 2020)\n5. Adult for whom previous conservative treatments were started for at least a month\n6. Mental and physical capability of the patient to handle the MiniGo by himself.\n7. Check of the anastomosis (no signs of leakage or clinical relevant stenosis) and absence of local recurrence by Rectal digital examination of the anastomosis, any other exam used in the current practice\n8. Patient affiliated to the health social security system\n\nExclusion Criteria:\n\n1. Contra-indication to use TAI\n2. Former use of TAI (post colo-rectal surgery)\n3. Clinically relevant stenosis\n4. Current metastatic disease or local recurrence\n5. Ongoing chemotherapy\n6. Postoperative radiotherapy for rectal cancer\n7. History of diarrhoeal disease\n8. Inflammatory bowel disease\n9. Dementia\n10. Spinal cord injury, multiple sclerosis, Parkinson's disease or other significant disease assessed to be a contributory cause to LARS symptoms.\n11. Patient with cancer recurrence\n12. Patient with a life expectancy \\\u003C 1 year\n13. Participating to another clinical trial for the treatment of LARS symptom\n14. Ongoing pelvic floor rehabilitation\u002Fbiofeedback\n15. Pregnancy or intention to become pregnant during the trial period\n16. Inability and unwillingness to give informed consent",{"count":183,"type":21},78,"OBSERVATIONAL","The purpose of this post-market clinical follow up study is to assess the efficacy on clinical symptoms of LARS of low volume Transanal Irrigation by MiniGo in conjunction with conservative treatment versus conservative treatment at 3 months.",[187,27,29],"Gastroenterology",[32,189,190,191],"Transanal Irrigation","Minigo","rectal cancer","2025-04-03",{"date":194,"type":42},"2025-04-11",{"date":196,"type":42},"2024-06-18",{"date":198,"type":21},"2026-12",{"name":200,"class":201},"Qufora A\u002FS","INDUSTRY",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":210,"sex":17,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":78},"100555970","effectiveness-of-pelvic-floor-exercise-to-prevent-lars-low-anterior-resection-syndrome-100555970","NCT06519006","Effectiveness of Pelvic Floor Exercise to Prevent LARS (Low Anterior Resection Syndrome)","Effectiveness of Pelvic Floor Exercise to Prevent LARS (Low Anterior Resection Syndrome) After Mini-invasive Low Anterior Resection in Patients With Rectal Cancer","CH1","Inclusion Criteria:\n\n* Cognitive functions make it possible to understand and sign the patient\\'s informed consent and consent to participate in the study\n* Surgical procedure - mini-invasive low anterior rectal resection\n\nExclusion Criteria:\n\n* not agreeing to participate in the study\n* request to practice pelvic floor exercises despite being in the control group\n* non-compliance\n* serious psychiatric diagnoses",true,"19 Years",{"count":213,"type":21},50,[62],"The main aim of this randomized study will be to determine the effectiveness of pelvic floor exercises on the incidence or severity of LAR syndrome in patients after mini-invasive rectal resection.\n\nThe main questions it aims to answer are:\n\n* Does pelvic floor exercise after low anterior resection prevent LARS (low anterior resection syndrome)?\n* What is the adherence of patients to prescribed home exercise after surgery?\n* Quality of life after LAR\n\nResearchers will compare the group of patients with pelvic floor exercises to those without and determine the occurrence and severity of LARS.\n\nParticipants will:\n\n* under the professional guidance of a physiotherapist, the day before surgery and in the first 4 postoperative days be educated to exercise the pelvic floor\n* continue exercise at home for a month (according to the instructions together with the infographic)",[217,27,218,29,114],"Prevention","Pelvic Floor Disorders",[220],"prevention, LARS, pelvic floor exercise, LAR","2024-07-19",{"date":223,"type":42},"2024-07-25",{"date":225,"type":42},"2024-04-01",{"date":227,"type":21},"2026-05",{"name":229,"class":49},"F. D. Roosevelt University Hospital",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":211,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":78},"100483654","5-ht3-receptor-antagonist-ramosetron-vs-loperamide-for-the-treatment-of-low-anterior-resection-syndromeralars-100483654","NCT05577845","5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)","Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial","RaLARS","Inclusion Criteria:\n\n* mid and low rectal cancer (AV\\\u003C15cm)\n* stage II, III, preop long-course CCRT, then ileostomy repair\n* about 1\\~12 months after operation (no stomy)\n* about 1\\~6 months after ileostomy repair\n* major LARS\n\nExclusion Criteria:\n\n* recurred rectal cancer\n* stage IV\n* IBD\n* uncontrolled preoperative fecal incontinence or constipation",{"count":239,"type":21},212,[62],"Safety \\& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial",[27],"2023-04-24",{"date":245,"type":42},"2023-04-25",{"date":247,"type":42},"2023-03-27",{"date":249,"type":21},"2032-12",{"name":251,"class":49},"Seoul National University Hospital"]